28 results about "Interferon alpha" patented technology

The invention belongs to the technical field of veterinary medicine, and provides a co-expressed recombinant porcine alpha and gamma interferon. The I-type interferon alpha and the II-type interferon gamma not only exert the anti-virus, anti-cell division and immune regulation effects of the interferon, but also can activate T cells and natural killer cells, and fully exert the multiple activities of the interferon. The two interferons are co-expressed in insect cells, the expression protein can be folded and then processed and modified, the structure of the expression protein is closer to a natural structure, the biological activity is high, the recombinant protein is easy to purify, the production scale is easy to expand, and live viruses or potential dangerous pathogens do not need to be treated, so that the production cost is reduced; by optimizing the production process and fermentation conditions, the quality and stability of the recombinant protein can be further improved.

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b, modified acetylated interferon alpha 2 b, and / or a mixture thereof is disclosed herein.

The present invention provides fusion proteins comprising human IFN-[alpha] 2, a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and to human IFN-[alpha] 2, and methods of using the same.

Methods of treating hepatitis delta virus (HDV) infection in a human subject are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of lonafarneb and ritonavir, with or without pegylated interferon alpha.

The invention relates to the technical field of medicines, and particularly discloses application of interferon alpha combined with stiripentanol in virus infection resistance. As an antiviral drug, interferon alpha has the problems of limited curative effect, remarkable side effect, narrow applicable crowd, inconvenience in medication and the like clinically. The invention finds that the accumulation of host lactic acid in the later stage of virus infection is a key negative factor, and lactic acid directly inhibits the antiviral activity of interferon alpha and induces inflammatory storm. Through combined use of a lactic dehydrogenase inhibitor stiripentol (Stiripentol, STP), lactic acid production is reduced, a lactic acid-mediated antiviral inhibition-inflammation promotion effect is reversed, and the antiviral activity of interferon alpha is enhanced and side effects are reduced. Experiments prove that the combined therapy can effectively inhibit virus replication and inflammatory factor expression, and a new strategy is provided for broad-spectrum antiviral therapy.

The modification of human interleukin-2 (IL-2) and interferon α (IFNα); the fusion protein formed by the modified IL-2, IFNα or IL-2 / IFNα dual factor and Fc; and the design, preparation and use of these fusion proteins. IFNα changes the binding ability of IFNα to its receptor through gene mutation to obtain a better fusion protein, which solves the shortcomings of weak specificity and large side effects of existing drugs.

Provided herein are methods for treating a brachyury-associated cancer or neoplasm, e.g., chordoma, with a type I interferon in a subject in need thereof. The methods further include treating the brachyury-associated cancer or neoplasm with interferon alpha or interferon beta by injection of interferon protein into a subject in need thereof, wherein the interferon can be an interferon polypeptide or an interferon nucleic acid formulated for expression.

The invention relates to a fusion protein for improving the antiviral titer of prokaryotically expressed porcine interferon-alpha, and belongs to the technical field of animal medicine. The fusion protein is an sIL-2-Thy alpha 1 fusion protein, and is a high-purity sIL-2-Thy alpha 1 protein obtained by connection and recombinant expression of an sIL-2 gene and a Thy alpha 1 gene, chromatographic purification by using Ni < 2 + > affinity resin, removal of a label by enzyme digestion and removal of endotoxin. The sIL-2-Thy alpha 1 fusion protein and the sIFN-alpha protein are combined into an antiviral composition, so that the inhibition effect of the sIFN-alpha on the swine vesicular stomatitis virus (VSV) can be remarkably enhanced, and a remarkable synergistic effect is achieved. The composition has unique advantages in the aspect of preventing and treating VSV infection. In addition, through innovative fusion protein design, the antiviral efficacy of interferon is improved, and the interferon has wide application prospects.

The present disclosure provides a method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of an immunotherapeutic, wherein the subject has been determined to have a T cell signature (TCS) comprising: (a) a composite expression level A comprising the expression of three or more genes selected from Thymocyte Expressed, Positive Selection Associated 1 (TESPA1), Cluster of Differentiation 28 (CD28), G Protein-Coupled Receptor 183 (GPR183), and Zeta-Chain-Associated Protein Kinase 70 (ZAP70) as measured by log2tpm corresponding to a composite log2tpm value of greater than or equal to 3.2; or (b) a composite expression level B comprising (i) the expression of three or more genes selected from TESPA1, CD28, GPR183 and ZAP70 as measured by log2tpm corresponding to a composite log2tpm value of greater than or equal to 3.2, minus (ii) the expression of Interferon Alpha Inducible Protein 27 (IFI27) gene as measured by log2tpm, wherein the composite expression level B corresponds to a value of greater than or equal to -0.25.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b with deamidated amino acids is disclosed herein.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a gel preparation for conditioning and preventing cervical HPV (human papillomavirus) in the gynecology department and a preparation process of the gel preparation. The gel preparation disclosed by the invention takes the fusion protein of the human interferon alpha-2b and the antibacterial peptide as an active ingredient, and has a good effect in the aspects of inhibiting the cell proliferation rate of Hela cells and reducing the HPV18 virus load in the Hela cells. Clinical experiment data show that the gel preparation for conditioning and preventing cervical HPV in the gynecology department is high in effective rate, and remarkable progress is made.

The present invention belongs to the field of biomedicine, and discloses molecular markers for predicting the therapeutic efficacy of interferon α on hepatitis B patients and their applications. Including: 1. A molecular marker combination for predicting the therapeutic efficacy of interferon α on hepatitis B patients, including BST2rs9576, and at least one other molecular marker. 2. Reagents and / or kits for detecting the above molecular marker combination, including reagents for detecting the molecular marker BST2rs9576. 3. A kit, including primers for detecting the molecular marker BST2rs9576. 4. The use of reagents for detecting molecular markers in the preparation of products for predicting the therapeutic efficacy of interferon α on hepatitis B patients, the molecular marker is BST2rs9576, and the reagents are primers for detecting BST2rs9576. The primers and products provided by the present invention can specifically and efficiently detect the polymorphic sites of molecular markers to achieve pre-treatment prediction.

Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-a) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

Provided herein are human interferon alpha-2 (IFNA2) variants that have decreased or no detectable binding to the human interferon-alpha / beta receptor beta 2 (IFNAR2) as compared to the wild-type human IFNA2 polypeptide. Also provided herein are fusion proteins comprising an antibody or fragment thereof, and a human IFNA2 variant, wherein the IFNA2 variant is covalently linked to the antibody, and wherein the IFNA2 variant has decreased or no detectable binding to the human interferon-alpha / beta receptor beta (IFNAR2) as compared to the wild-type human IFNA2 polypeptide.

The application discloses a method for improving the antiviral efficacy of rainbow trout type I interferon alpha protein and belongs to the technical field of medical drugs. The method is that resistant starch and carboxymethyl chitosan are used as microencapsulation materials to perform microencapsulation treatment on the interferon alpha protein. A new combination mode of coating materials, resistant starch-carboxymethyl chitosan, is adopted, wherein the resistant starch has excellent enzyme resistance and colon targeting property, can prolong the half-life of the interferon protein in the body and has a long action time. The carboxymethyl chitosan has excellent water solubility and film forming property. After the two composite materials are used for coating, the highest encapsulation rate can reach 23.09%, the highest drug loading rate can reach 81.20%, and the effect is remarkable. The prepared oral interferon microcapsules by using the method are simple in use, have more obvious antiviral effect and have excellent application prospect, and a new idea is provided for microencapsulation coating.

The invention provides a construction method of a Zika virus (ZIKV) infected rat model, and belongs to the technical field of biology. The ZIKV challenge animal model is obtained by inoculating ZIKV to a rat with deletion of interferon alpha and beta receptor subunit 1 (Ifnar1). Compared with an Ifnar1-deficient rat without injection of ZIKV, after inoculation of ZIKV, obvious ZIKV load can be detected in blood, liver, spleen, reproductive organ and brain tissue of the rat, moreover, the spleen is obviously swollen, spleen small body is reduced, a large amount of inflammatory cell infiltration occurs in the liver tissue, the mRNA level of inflammation-related molecules is obviously increased, and the Ifnar1-deficient rat has obvious ZIKV load. It is shown that the ZIKV challenge model is successfully constructed, and the ZIKV challenge model can be applied to related researches of ZIKV infection mechanisms, vaccine research and development, anti-ZIKV drug research and development and the like.

This invention relates to use of interferon-polymer conjugates described in the specification to treat idiopathic myelofibrosis, polycythaemia vera and essential thrombocythaemia.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b with modified Nle substituted, Gly at position 45 substituted to Asp and / or Asn at position 66 substituted to Lys substituted modified interferon alpha 2 b, and / or a mixture thereof is disclosed herein.

The application discloses application of a probiotic preparation in vaginal flora regulation and anti-HPV, and relates to the technical field of biological medicine; a pharmaceutical composition for assisting in treating high-risk human papilloma virus infection, the pharmaceutical composition comprising: interferon, which is recombinant human interferon alpha-2b; and a vaginal probiotic preparation, which comprises an effective dose of lactobacillus live bacteria; wherein the interferon and the probiotic preparation are formulated into a combined preparation or separate preparations for vaginal administration. The application discloses a new mechanism that the probiotic activates specific immune pathways to synergistically resist viruses, and proves excellent curative effects of the combined therapy; in traditional cognition, the probiotic mainly restores flora balance through occupying competition and acid production.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b with deamidated amino acids is disclosed herein.

The invention provides a traditional Chinese medicine immunopotentiator for animal vaccines, and belongs to the technical field of animal vaccines. The traditional Chinese medicine immunopotentiator is prepared by compounding ginsenoside, polygonatum polysaccharide and atractylodes macrocephala koidz polysaccharide and carrying out digestion treatment by using helicase. In-vitro tests detect that the hemolysis rate of the traditional Chinese medicine immunopotentiator digested by helicase is reduced to 3.78% and is greatly reduced compared with the hemolysis rate of a conventional traditional Chinese medicine immunopotentiator which is not digested by helicase; and the helicase digestion traditional Chinese medicine immunopotentiator can improve the expression levels of interferon alpha and interferon gamma of the porcine lymphocytes and enhance the immune response of the porcine lymphocytes. The porcine epidemic diarrhea virus subunit vaccine containing the helicase digestion traditional Chinese medicine immunopotentiator is good in safety, and the titer of a porcine epidemic diarrhea virus neutralizing antibody of immune piglet serum is remarkably improved.

The invention discloses an interferon and exosome aerosol inhalation preparation as well as a preparation method and application thereof. The preparation is prepared from the following components: 5 to 15 mu g / mL of interferon alpha, 0.1 to 0.5 mg / mL of exosome, 0.2 to 0.8 percent of NSCS-PNIPAM, 0.3 to 1 percent of mannitol, 0.01 to 0.05 percent of polymer stabilizer, 0.5 to 2 mM of phosphate buffer solution and 0.02 to 0.1 percent of surfactant. The invention belongs to the technical field of biological medicine. According to the invention, multi-dimensional improvement of material performance is realized, the synthesized N-succinyl chitosan-poly (N-isopropylacrylamide) grafted copolymer (NSCS-PNIPAM) combines the biocompatibility of chitosan with the environmental responsiveness of PNIPAM, so that the biodegradability of the material is improved, and the biodegradability of the material is improved. The problems of exosome membrane structure damage and interferon functional activity reduction possibly caused by mechanical shearing force and thermodynamic factors are effectively solved.

The invention belongs to the technical field of protein engineering, and particularly relates to a sheep alpha interferon and sheep interleukin 2 fusion protein and a preparation method thereof. The preparation method comprises the following steps: connecting a ShIFNalpha-IL2 fragment to a pET32a vector to obtain a recombinant plasmid pET32a-ShIFNalpha-IL2; transforming into an E.coli BL21 competent cell, and inducing expression; and centrifuging, collecting the strain, resuspending, carrying out ultrasonic treatment, injecting inclusion body BB, completely draining, injecting the supernatant filtrate, completely draining, injecting inclusion body BB, washing, and eluting the target protein in the column by using inclusion body EB to obtain the ShIFNalpha-IL2 recombinant protein. Through SDS-PAGE electrophoresis detection, separation and purification of the fusion protein of the sheep interferon alpha and the sheep interleukin 2 are realized, and the target protein with relatively high purity is obtained. The fusion protein also has a high expression level, can effectively prolong the retention time of interferon in vivo, and improves the half-life period of interferon.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b, modified acetylated interferon alpha 2 b, and / or a mixture thereof is disclosed herein.

The present invention belongs to the field of biomedicine, and discloses molecular markers and their applications for predicting the therapeutic efficacy of interferon α on hepatitis B patients. Including: 1. A molecular marker combination for predicting the therapeutic efficacy of interferon α on hepatitis B patients, including ALPK1rs35389530, and at least one other molecular marker. 2. Reagents and / or kits for detecting the above molecular marker combination, including reagents for detecting ALPK1rs35389530. 3. A kit, including primers for detecting the molecular marker ALPK1rs35389530. 4. The use of reagents for detecting molecular markers in the preparation of products for predicting the therapeutic efficacy of interferon α on hepatitis B patients, the reagents being primers for detecting ALPK1rs35389530. The primers and products of the present invention can specifically and efficiently detect the polymorphic sites of molecular markers to achieve pre-treatment prediction.